Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18418890 | 0.83 | GAA (0.36) | KDM5BCYP2C19ABL1CD274GAA | |
| SCHEMBL1475184 | 0.83 | ALDH1A1 (0.36) | KDM5BCYP2C19ABL1CD274GAA | |
| SCHEMBL22325063 | 0.81 | GAA (0.38) | KDM5BCYP2C19ABL1CD274GAA | |
| SCHEMBL30376074 | 0.78 | KDM5B (0.36) | KDM5BCYP2C19ABL1CD274GAA | |
| SCHEMBL31083337 | 0.78 | ALDH1A1 (0.35) | KDM5BCYP2C19ABL1CD274GAA | |
| SCHEMBL18421834 | 0.78 | ALDH1A1 (0.33) | KDM5BCYP2C19ABL1CD274GAA | |
| SCHEMBL32684090 | 0.77 | CYP2C19 (0.33) | KDM5BCYP2C19ABL1CD274GAA | |
| SCHEMBL21663744 | 0.77 | RET (0.32) | CYP2C19ABL1 | |
| SCHEMBL26108637 | 0.77 | CYP2C19 (0.32) | CYP2C19ABL1 | |
| SCHEMBL1476580 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | KDM5B 4422/4885CYP2C19 411/4885ABL1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.